gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · LYELHealthcarePharmaceuticals

Lyell Immunopharma, Inc. Common Stock (LYEL)

$15.43+43.27%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$15.43▼ 3.26% in range
Nov 4, 2025Low $7.51 · High $38.60Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Lyell Immunopharma closed at $15.43 on Nov 4, up 43.27%, 60.0% below its 52-week closing high. Volume of 1.1M shares was 6.89× its 20-day average (well above normal).

Split-adjusted performance: +79.2% over one month, -26.0% over six months, -6.8% over one year.

In the quarter ended Jun 30, 2026, revenue was $4K, down 50.0% from a year earlier, with a net margin of -1118875.0%.

Short interest was 1.4M shares at the Oct 15 settlement, up 10.7% from the prior report (15.8% of float, 7.8 days to cover).

Market cap$378.1M24.5M shares
Revenue · quarter$4.0K−50.0% YoY
Diluted EPS$-1.92—
P/E · TTM—P/S 14,004.2×
Net margin-1,118,875.0%Gross 100.0%
Dividend yieldNone
52-week range7.51 – 38.60−60.0% from high
Volume1.1M6.89× 20-day avg
Volatility · 60d101.1%Annualised
Short % of float15.8%7.9 days to cover
Net cash$204.1MCash $204.1M
Next earnings—Not scheduled
Split-adjusted performance
1W +41.2%1M +79.2%3M +8.6%6M −26.0%YTD −49.9%1Y −6.8%3Y −56.9%5Y −94.6%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum49
Revenue growth22
Net margin0
Value (low P/E)—
Size57

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short1.4M+10.7% vs prior
Days to cover7.9Settled Oct 15
% of float15.8%
Short vol. 10d51.1%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
LYELLyell Immunopharma$15.43+43.27%−26.0%−50.0%−1118875.0%—$378.1M
AVTXAvalo Therapeutics$7.07−2.48%−67.6%———$379.2MCompare
RZLTRezolute, Inc. Common Stock (NV)$3.96−1.25%+26.1%———$383.0MCompare
MPLTMapLight Therapeutics$6.71−1.47%−76.9%———$372.9MCompare
CTNMContineum Therapeutics$9.79+1.03%−34.5%———$368.3MCompare
BLSMBlossomHill Therapeutics$12.38−0.24%————$393.5MCompare
AVIRAtea Pharmaceuticals$4.46+6.95%−21.1%———$357.7MCompare
IRDOpus Genetics$4.27+8.65%−18.8%−73.8%−1072.6%—$355.2MCompare
ASMBAssembly Biosciences$19.87−0.25%−36.6%+38.9%−28.8%—$404.6MCompare

News about Lyell Immunopharma

All news →
Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 CongressGlobeNewswire Inc. · Jun 12, 2026▲ PositiveLyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 ExpansionGlobeNewswire Inc. · Jun 8, 2026▲ PositiveLyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business OfficerGlobeNewswire Inc. · Mar 9, 2026▲ Positive

Quick answers

What does Lyell Immunopharma do?
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL).
What is LYEL's market cap?
$378.11M, based on the Nov 4 close of $15.43.
Does Lyell Immunopharma pay a dividend?
No regular cash dividend has been paid in the last year.
How much of LYEL is sold short?
1.4M shares, 15.8% of float, as of Oct 15, 2026.
What sector is LYEL in?
Healthcare, in the Pharmaceuticals industry.

About Lyell Immunopharma

Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

HQ: South San Francisco, CA161 employeesListed Jun 17, 2021lyell.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology